CD33 and acute myeloid leukemia: For instance, CLL1‐KO AML cells show significantly reduced susceptibility to CLL1‐targeted CAR‐T‐cell killing, while retaining sensitivity to CAR‐T cells targeting alternative antigens (e.g., CD33 or CD123).18, 24